Clinical Trial Update: Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating re-administration of C134 in patients with recurrent glioblastoma and related brain gliomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme
• Gliosarcoma
• Malignant Glioma

Drugs mentioned

• C134

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain | Phase 1 | Status: TERMINATED